Recombinant Anti-CD16 x Anti-CD30 Bispecific Antibody (F(ab')2-scFv2) is designed to be expressed as two chains combined via a hinge region. The scFv of the anti-CD16 specificity is fused to the C terminus of the anti-CD30 Fab fragment, or vice versa. This format comprises four binding sites (two same scFv regions and two same Fab fragments), two for each antigen. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.